FDA Peptide Status in 2026: The Category 2 Removals, the July Votes, and What Actually Changed

Are peptides like BPC-157 legal in the US in 2026?

That is the whole story in five sentences. Hold onto it, because most of what shows up for these searches is written by clinics and sellers who make money from the answer. What follows is the timeline, how each vote went, what the lists mean and what would have to happen next. Every claim links to the FDA's own pages or to reporting that quotes them.

What the 503A bulk list and 'Category 2' mean

Pharmacies that mix drugs for single patients work under a part of US law called section 503A. They can only use raw ingredients that are part of an approved drug, that have an official quality standard, or that are on the FDA's approved ingredient list, called the 503A Bulks List. Ingredients put forward for that list go into holding groups while the FDA looks at them. Category 1 ingredients can be used while the FDA reviews them. Category 2 ingredients raised serious safety worries and cannot be used. In September 2023, the FDA put BPC-157 and a group of other peptides into Category 2. That is what pushed them out of many clinics and online health services.

The FDA's 503A bulk drug substances page is the main source for all of this.

What happened in April 2026

Law firm summaries at the time listed twelve substances. Published lists disagree on two of the twelve (some name PEG-MGF, others MK-677), so we list only the ones every source agrees on: BPC-157, TB-500, KPV and the peptides that went on to the July meeting. See the Orrick summary, FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings, and the April 2026 FDA Law Blog coverage.

What did the FDA peptide panel vote in July 2026?

The meeting page and the staff papers are on the FDA site: July 23 to 24, 2026 PCAC meeting. The BPC-157 staff paper (FDA media 193343) is worth reading in full. FDA staff found no good studies in people. They also found products on the market whose lab certificates did not match what the label said was inside.

Why did the committee vote against its own reviewers?

Headlines usually leave that reasoning out and stop at 'the panel overruled FDA scientists'. Both sides are worth hearing. On the yes side, panel member David Pope argued for putting the decision 'back into the hands of the patient, the physician and the pharmacist'. Haleem Mohammed said his vote was about keeping patients as safe as possible, given what they are already buying. On the no side, Brian Lee warned that the public would read the vote as proof the peptides work, and that serious side effects could be missed when people report their own problems. Josh Mailman said he was 'voting on something here, but I don't know what that something is'. The FDA's worry was as much about what these are as what they do. Staff said there is no agreed chemical formula for several of them, so a pharmacy cannot check what it is making (Pharmaceutical Executive, July 2026). The same report says one member sat out the BPC-157, KPV and TB-500 votes, and two sat out MOTS-c.

Reading the votes as a science finding either way is a mistake. The panel was not asked whether these peptides work, and it did not answer that. It answered a supply question. The members split on which source does less harm while the evidence stays where it is.

What this does not mean

• It does not mean any of these peptides is approved, safe or proven to work. Advisory panels vote on whether pharmacies may use an ingredient. They do not check products or set doses.
• It does not mean a clinic can have them made today. The FDA must write a new rule to add them to the approved ingredient list, and in the past that has taken years.
• It does not change anything about vials sold online. A product labeled 'for research use only' becomes an unapproved drug the moment it is sold for people to use. That label is a sales trick, not a legal category (see Johns Hopkins on how the FDA regulates peptides and Healthline on peptide legality).
• It does not create any evidence in people. For BPC-157, that evidence is still one report on 12 patients with nobody to compare them against, according to a 2025 review.

What would have to happen next

1. 01The FDA decides whether to take the panel's advice. It does not have to.
2. 02If it takes any of the advice, it proposes a rule adding that peptide to the approved ingredient list, asks the public for comments and then issues a final rule.
3. 03Pharmacies could then make that peptide for single prescriptions. Even then, it would not be an approved drug with a label, a standard dose or a maker who is legally on the hook.

We will update this page, and the date it was last changed, when any of those steps happens. The change log is at the bottom.

Which peptides are FDA-approved in 2026?

For the full list with evidence grades, filter the compound database by FDA status, or read the profiles for orforglipron, elamipretide and navepegritide.

Change log

• September 8, 2026: first published. Covers the April 2026 Category 2 removals and the July 23 to 24, 2026 advisory panel votes.
• September 27, 2026: rewritten in plain English. No facts changed.